These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 18021340)

  • 21. The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer.
    Russo D; Miranda I; Ruocco C; Battaglia Y; Buonanno E; Manzi S; Russo L; Scafarto A; Andreucci VE
    Kidney Int; 2007 Nov; 72(10):1255-61. PubMed ID: 17805238
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients.
    Block GA; Raggi P; Bellasi A; Kooienga L; Spiegel DM
    Kidney Int; 2007 Mar; 71(5):438-41. PubMed ID: 17200680
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Treatment with phosphate binder (sevelamer hydrochloride, calcium carbonate) based on PTH].
    Sato M; Fukazawa S; Yasuda T; Akatsuka T; Tozawa S; Niida Y; Hashimoto N; Mochizuki T; Koike T
    Clin Calcium; 2005 Sep; 15 Suppl 1():23-8; discussion 28-9. PubMed ID: 16272625
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data.
    St Peter WL; Liu J; Weinhandl E; Fan Q
    Am J Kidney Dis; 2008 Mar; 51(3):445-54. PubMed ID: 18295060
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sevelamer hydrochloride use and circulating endotoxin in hemodialysis patients: a pilot cross-sectional study.
    Sun PP; Perianayagam MC; Jaber BL
    J Ren Nutr; 2009 Sep; 19(5):432-8. PubMed ID: 19464926
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Buffering effects of calcium carbonate as clarified by sevelamer hydrochloride monotherapy.
    Akatsuka T; Mochizuki T; Koike T
    Ther Apher Dial; 2008 Jun; 12(3):216-25. PubMed ID: 18503699
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Two year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density.
    Asmus HG; Braun J; Krause R; Brunkhorst R; Holzer H; Schulz W; Neumayer HH; Raggi P; Bommer J
    Nephrol Dial Transplant; 2005 Aug; 20(8):1653-61. PubMed ID: 15930018
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term sevelamer treatment lowers serum fibroblast growth factor 23 accompanied with increasing serum Klotho levels in chronic haemodialysis patients.
    Lin HH; Liou HH; Wu MS; Lin CY; Huang CC
    Nephrology (Carlton); 2014 Nov; 19(11):672-8. PubMed ID: 25113414
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Calcium load during administration of calcium carbonate or sevelamer in individuals with normal renal function.
    Heinrich T; Heidt H; Hafner V; Schmidt-Gayk H; Jenetzky E; Walter-Sack I; Mikus G; Bommer J
    Nephrol Dial Transplant; 2008 Sep; 23(9):2861-7. PubMed ID: 18388122
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The use of sevelamer in the treatment of resistant hyperphosphataemia in children with chronic renal disease].
    Runowski D; Jachimiak B; Cieślak-Puchalska A; Pacanowska B; Zimoń T
    Pol Merkur Lekarski; 2009 Apr; 26(154):318-21. PubMed ID: 19580197
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Accelerated vascular calcification and relative hypoparathyroidism in incident haemodialysis diabetic patients receiving calcium binders.
    Galassi A; Spiegel DM; Bellasi A; Block GA; Raggi P
    Nephrol Dial Transplant; 2006 Nov; 21(11):3215-22. PubMed ID: 16877490
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of sevelamer on mineral and lipid abnormalities in hemodialysis patients.
    Hamida FB; Fatma LB; Barbouch S; Kaaroud H; Helal I; Hedri H; Abdallah TB; Maiz HB; Kheder A
    Saudi J Kidney Dis Transpl; 2008 Mar; 19(2):183-8. PubMed ID: 18310864
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Factors associated with mortality in patients new to haemodialysis.
    Spiegel DM; Raggi P; Smits G; Block GA
    Nephrol Dial Transplant; 2007 Dec; 22(12):3568-72. PubMed ID: 17617651
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Switching from calcium carbonate to sevelamer hydrochloride has suppressive effects on the progression of aortic calcification in hemodialysis patients: assessment using plain chest X-ray films.
    Izumi M; Morita S; Nishian Y; Miyamoto T; Kasumoto H; Oue M; Hori K; Kitamura R; Yamamoto S; Nakanishi T
    Ren Fail; 2008; 30(10):952-8. PubMed ID: 19016145
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardiac surgery in patients on dialysis: decreased 30-day mortality, unchanged overall survival.
    Bechtel JF; Detter C; Fischlein T; Krabatsch T; Osswald BR; Riess FC; Scholz F; Schönburg M; Stamm C; Sievers HH; Bartels C
    Ann Thorac Surg; 2008 Jan; 85(1):147-53. PubMed ID: 18154800
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mortality in kidney disease patients treated with phosphate binders: a randomized study.
    Di Iorio B; Bellasi A; Russo D;
    Clin J Am Soc Nephrol; 2012 Mar; 7(3):487-93. PubMed ID: 22241819
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of sevelamer hydrochloride and sevelamer carbonate: risk of metabolic acidosis and clinical implications.
    Pai AB; Shepler BM
    Pharmacotherapy; 2009 May; 29(5):554-61. PubMed ID: 19397463
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phosphate binders and metabolic acidosis in patients undergoing maintenance hemodialysis—sevelamer hydrochloride, calcium carbonate, and bixalomer.
    Sanai T; Tada H; Ono T; Fukumitsu T
    Hemodial Int; 2015 Jan; 19(1):54-9. PubMed ID: 24980286
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapy outcome in peritoneal dialysis patients transferred from haemodialysis.
    Liberek T; Renke M; Skonieczny B; Kotewicz K; Kowalewska J; Chmielewski M; Kot J; Lichodziejewska-Niemierko M; Rutkowski B
    Nephrol Dial Transplant; 2009 Sep; 24(9):2889-94. PubMed ID: 19342418
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New strategy to attenuate pulse wave velocity in haemodialysis patients.
    Takenaka T; Suzuki H
    Nephrol Dial Transplant; 2005 Apr; 20(4):811-6. PubMed ID: 15772266
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.